These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20919855)

  • 1. Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden.
    Lazarevic VL; Hägglund H; Remberger M; Wahlin A; Hallböök H; Juliusson G; Kimby E; Malm C; Omar H; Johansson JE
    Leuk Lymphoma; 2011 Jan; 52(1):69-71. PubMed ID: 20919855
    [No Abstract]   [Full Text] [Related]  

  • 2. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
    Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
    Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follicular Lymphoma: Redefining Prognosis, Current Treatment Options, and Unmet Needs.
    Welaya K; Casulo C
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):627-638. PubMed ID: 31229159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
    Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
    J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.
    Lunning MA; Migliacci JC; Hilden P; Devlin SM; Castro-Malaspina H; Giralt S; Perales MA; Zelenetz AD; Moskowitz CH; Sauter CS
    Br J Haematol; 2016 Apr; 173(2):260-4. PubMed ID: 26847389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.
    Bourcier J; Gastinne T; Leux C; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Voldoire M; Guillaume T; Peterlin P; Gallas P; Garnier A; Maisonneuve H; Moreau P; Juge-Morineau N; Jardel H; Chevallier P; Moreau P; Le Gouill S
    Ann Hematol; 2016 Aug; 95(8):1287-93. PubMed ID: 27297970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma.
    Andresen S; Brandt J; Dietrich S; Memmer ML; Ho AD; Witzens-Harig M
    Leuk Lymphoma; 2012 Mar; 53(3):386-93. PubMed ID: 21864036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin.
    Stein RS; Greer JP; Goodman S; Kallianpur A; Ahmed MS; Wolff SN
    Bone Marrow Transplant; 1999 Feb; 23(3):227-33. PubMed ID: 10084253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
    Krishnan A; Nademanee A; Fung HC; Raubitschek AA; Molina A; Yamauchi D; Rodriguez R; Spielberger RT; Falk P; Palmer JM; Forman SJ
    J Clin Oncol; 2008 Jan; 26(1):90-5. PubMed ID: 18025438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of follicular non-Hodgkin's lymphoma: the old and the new.
    Friedberg JW
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S2-6. PubMed ID: 18760706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
    Kuruvilla J; Pond G; Tsang R; Gupta V; Lipton JH; Messner HA
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):775-82. PubMed ID: 18541196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.
    Andreadis C; Schuster SJ; Chong EA; Svoboda J; Luger SM; Porter DL; Tsai DE; Nasta SD; Elstrom RL; Goldstein SC; Downs LH; Mangan PA; Cunningham KA; Hummel KA; Gimotty PA; Siegel DL; Glatstein E; Stadtmauer EA
    Bone Marrow Transplant; 2005 Dec; 36(11):955-61. PubMed ID: 16205727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of follicularity on autologous transplantation for large-cell non-Hodgkin's lymphoma.
    Vose JM; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Chan WC; Greiner TC; Armitage JO
    J Clin Oncol; 1998 Mar; 16(3):844-9. PubMed ID: 9508164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.
    Brown JR; Feng Y; Gribben JG; Neuberg D; Fisher DC; Mauch P; Nadler LM; Freedman AS
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1057-65. PubMed ID: 17697968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment.
    Sancho JM; García O; Mercadal S; Pomares H; Fernández-Alvarez R; González-Barca E; Tapia G; González-García E; Moreno M; Domingo-Domènech E; Sorigué M; Navarro JT; Motlló C; Fernández-de-Sevilla A; Feliu E; Ribera JM
    Leuk Res; 2015 Aug; 39(8):853-8. PubMed ID: 26122511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
    Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
    Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report.
    Marangon M; Pellegrini C; Argnani L; Zinzani PL
    Tumori; 2017 Nov; 103(Suppl. 1):e41-e43. PubMed ID: 28967090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive treatment in follicular non-Hodgkin's lymphoma.
    Schouten HC
    Br J Hosp Med; 1996 Nov 20-Dec 10; 56(10):525-8. PubMed ID: 8958406
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.